FDA approves first generic Advair Diskus

4 Feb 2019

Mylan's Wixela Inhub is the first FDA-approved therapeutically equivalent generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for certain patients with asthma or COPD.

Mylan has announced the FDA approval of Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), the first generic of Advair Diskus.

FDA approves first generic Advair Diskus
Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP)

Wixela Inhub will launch in the second half of February incorporating the latest safety information required by FDA last month, which prompted an amendment to the label for certain inhaled corticosteroids, including Advair Diskus and any generic versions. Wixela Inhub will be available in the 100 mcg/50 mcg, 250 mcg/50 mcg and 500 mcg/50 mcg strengths for asthma patients and the 250 mcg/50 mcg strength for COPD patients.

Mylan CEO Heather Bresch commented: "Mylan remains steadfast in its efforts to expand patient access to medicines, and the FDA approval of Wixela Inhub reinforces our commitment to provide patients greater choice and lower-cost alternatives. This milestone represents the culmination of an extensive R&D program and Mylan's more than $700 million of investment. We're proud of our Wixela Inhub team, who worked tirelessly and in close collaboration with the FDA to bring this important medicine to market and add it to our growing global portfolio of more than 700 respiratory products. As one of the leading providers of prescription medicines in the US, we continue to execute on our mission and do our part to reduce costs for patients and identify pathways that help increase sustainability for the US healthcare system overall."

Mylan President Rajiv Malik added: "We're pleased to offer the first FDA-approved generic of Advair Diskus, one of the leading treatments for asthma and COPD management today. We've long been confident in the science around this product and are proud of the dedication of our scientific teams to bring Wixela Inhub to market. This complex product required a rigorous R&D program spanning over a decade and close collaboration with FDA to define the regulatory pathway. We also are proud to manufacture Wixela Inhub in our own state-of-the-art plant. This approval reinforces our ongoing commitment to increase access to more affordable treatment options for patients."

"Patients enrolled in clinical trials found Wixela Inhub easy-to-use and highly effective at controlling their asthma in a clinical bioequivalence study. Asthma and respiratory specialists and primary care providers welcome this generic alternative to benefit many patients with asthma and COPD. We have waited for years for generic inhalers to emerge in respiratory medicine," said Edward Kerwin, MD of Crisor, a division of the Clinical Research Institute located in Medford, Ore. and a Clinical Investigator on the Wixela Inhub clinical program.

Advair Diskus had US sales of $4.2 billion for the 12 months ending 30 November 2018, according to IQVIA.

Read More

Related news

Pinpoint secures new investment to develop ground-breaking products

Pinpoint secures new investment to develop "ground-breaking" products

29 Nov 2019

The financial backing will help the company to develop a new generation of microbial air monitors that enables continuous monitoring as demanded by the Annex 1 revision.

Read more 
New single-use mixing system offers rapid and homogenous mixing

New single-use mixing system offers rapid and homogenous mixing

28 Nov 2019

ClearMixx performs liquid/liquid and powder/liquid mixing, with a dispersion plate able to efficiently mix the most challenging buffer, media and biopharmaceutical ingredients.

Read more 
Worldwide event predicts global pharma trends for 2020

Worldwide event predicts global pharma trends for 2020

27 Nov 2019

Content sessions identify value-added medicines, preventive drugs, early diagnostics and patient experience as some of the trends for the year ahead.

Read more 
UK’s life sciences sector continues to attract talent despite Brexit fear

UK’s life sciences sector continues to attract talent despite Brexit fear

26 Nov 2019

The largest area of growth has been within biotechnology companies, where job openings increased by 35%.

Read more 
Dr Reddy’s enters Nutrition Segment with diabetes drink

Dr Reddy’s enters Nutrition Segment with diabetes drink

25 Nov 2019

The company's diabetes nutrition drink, Celevida, is formulated to help manage blood glucose levels.

Read more 
India pharma forecast to grow strongly in 2020

India pharma forecast to grow strongly in 2020

22 Nov 2019

The rise in exports growth potential is believed to be in response to concerted reforms by the CDSCO and industry quality improvements in the last few years.

Read more 
Heraeus expands its platinum-based HPAPI capacity

Heraeus expands its platinum-based HPAPI capacity

21 Nov 2019

Company's multimillion euro investment will enable it to meet growing market demands from clients providing cancer treatments.

Read more 
Thermo Fisher Scientific opens Customer Solution Center in China

Thermo Fisher Scientific opens Customer Solution Center in China

20 Nov 2019

The new center will provide expertise in critical analytical processes and specialized workflows.

Read more 
Is Recipharm on the cusp of becoming a leading inhalation company?

Is Recipharm on the cusp of becoming a leading inhalation company?

19 Nov 2019

The CDMO offers to acquire Consort Medical to become a Top Five global CDMO player.

Read more 
Hovione completes pilot-scale blister manufacturing for its 'green' DPI

Hovione completes pilot-scale blister manufacturing for its 'green' DPI

19 Nov 2019

The device's blister is designed to provide flexibility to pharmaceutical partners delivering a wide range of inhaled drugs for both acute and chronic respiratory treatments.

Read more